Review
Open access
Sep 2026
ADAM17 as a proteolytic rheostat linking inflammation, tissue repair, and failure of inflammatory resolution in liver injury and fibrosis.
This framework suggests that therapeutic strategies should move beyond broad ADAM17 inhibition toward context-, cell-, or substrate-selective modulation that limits pathogenic signaling while preserving inflammation-resolving and tissue-repair functions.
Xiao-Dan Jiang, Jin-Xin Ma, Zhe-Jun Liu et al.
· Frontiers in Pharmacology · 0 citations